In this video, I discuss ribociclib and abemaciclib in early stage HR /HER2- breast cancer. Both are CDK 4/6 inhibitors which interfere with the cell cycle and are used in combination with endocrine therapy to decrease the risk of recurrence. Ribociclib: 400 mg daily 21 days on/7 days off for 3 years At 5 years: absolute improvement in invasive disease free survival (survival without disease) was 4.5% in patients receiving ribociclib (81% in endocrine therapy alone versus 85.5% in ribociclib end

Ribociclib plus letrozole is tied to longer progression-free survival than letrozole alone for advanced breast cancer, but whether that translates to an overall survival benefit is unknown. New research findings are summarized in a short video. https://nej.md/3MdbgW7 | The New England Journal of Medicine

⭐️ Update on longer outcomes with ribociclib (Kisqali) and abemaciclib (Verzenio) in hormone receptor positive/HER2 negative early stage breast cancer. ⭐️ These are CDK 4/6 inhibitors given in conjunction with endocrine therapy to reduce risk of recurrence. (CDK 4/6 inhibitors are standard of care in the treatment HR metastatic breast cancer as well). In early stage BC, abemaciclib is taken for 2 years and ribociclib for 3 years. In this video, I share with you recent updates (they are positive!